In case you missed it, a new report from Fierce Pharma details the most
expensive prescription drugs in the United States in 2025.





 

August 15, 2025



TOPLINE



In case you missed it, a new report
<[link removed]>
from Fierce Pharma details the most expensive prescription drugs in the United
States in 2025. The list, dominated by multimillion-dollar gene therapies,
provides an opportunity to review the growing gap between Big Pharma’s
out-of-control prices, especially on newly launched brand name products, and
their clinical value for patients.



Many of the highest priced treatments on the list have been evaluated for
cost‑effectiveness relative to clinical benefit by the Institute for Clinical
and Economic Review (ICER), which issues a health‑benefit price benchmark
(HBPB) to reflect a drug’s fair value. Time and again, Big Pharma’s list prices
soar far beyond these benchmarks for a fair price.



Examples of the disparities between Big Pharma’s prices and estimates for a
fair price among the highest price treatments this year include:

* Lenmeldy ($4.2M
<[link removed]>
Price vs.$2.3M
<[link removed]>
Estimate for Fair Price)
* Hemgenix ($3.5M
<[link removed]>
Price vs.$2.9M
<[link removed]>
Estimate for Fair Price)
* Lyfgenia ($3.1M
<[link removed]>
Price vs.$1.3M
<[link removed]>
Estimate for Fair Price)
* Roctavian ($2.9M
<[link removed]>
Price vs.$1.9M
<[link removed]>
Estimate for Fair Price)
* Zynteglo ($2.8M
<[link removed]>
Price vs.$2.1M
<[link removed]>
Estimate for Fair Price)
* Casgevy ($2.2M
<[link removed]>
Price vs.$1.3M
<[link removed]>
Estimate for Fair Price)
Lenmeldy, Hemgenix and Roctavian all entered the market in 2023 with launch
prices outpacing their fair price estimates. Read the full report from Fierce
PharmaHERE
<[link removed]>.
Get a Dose of Reality on Big Pharma’s increasingly out-of-control launch
prices, and egregious prices unjustified by clinical benefitHERE
<[link removed]>
.



QUOTES OF THE WEEK



"Big Pharma companies not only set high prices for drugs, but also
continuously raise them. For example, EpiPen prices skyrocketed from about $100
in 2007 to $650 in 2021, even as parents face rising allergy diagnoses in kids.
Additionally, inhalers cost American families up to 30 times more than those in
Europe, despite being on the market for decades."



- Ronald Bachman, President and CEO of Healthcare Visions
<[link removed]>



DATA POINTS YOU SHOULD KNOW



$2.32 Million



The price Big Pharma giant Novartis placed on rare disease gene therapy
Zolgensma, despite expertestimates
<[link removed]>
for a fair price falling between $310,000 and $900,000.



TWEETS OF THE WEEK



@USPTO <[link removed]>: “The USPTO hosted a
listening session about ways to make prescription drugs more affordable for
Americans by promoting competition, in line with President’s Trump’s Executive
Order on Lowering Drug Prices by Once Again Putting Americans First. Read more:
[link removed] <[link removed]>”



@Runaway_Rx <[link removed]>: “💸
According to a new report from I-MAK, just four years of delayed competition
for Eliquis will drive over $39 billion in U.S. revenue for #BigPharma while
they maintain their patent-protected monopoly and high prices. That’s the cost
of patent abuse—and health plan members are footing the bill.”



ROAD TO RECOVERY



The Center Square: Congress Must Reduce Prescription Drug Costs
<[link removed]>



President Trump took decisive action last week to address delays by
pharmaceutical companies, issuing letters to 17 pharmaceutical companies
demanding they comply with the directives outlined in the executive order to
lower prescription drug prices by Sept. 29, or risk government action.
Unfortunately for Americans, the longer drug companies drag their feet, the
longer they’ll pay sky-high drug prices, effectively subsidizing discounted
prices abroad. According to one study, prescription drug prices are, on
average, 2.78 times higher in the U.S. than in 33 other high-income countries.
According to the Organization for Economic Co-operation and Development, the
gap is even larger for brand-name drugs, with U.S. brand prices at least 3.22
times higher on average.



PHARMA’S POOR PROGNOSIS



Fierce Pharma: Most Expensive Drugs In The US In 2025
<[link removed]>



With more and more expensive gene therapies hitting the market, one-dose,
curative treatments are continuously shuffling the list of the U.S.’
highest-priced drugs. In just two years, half of Fierce Pharma’s 2023 list of
the most expensive drugs has been replaced with a fresh crop of newer, pricier
treatments. Each of the drugs on this year’s list are one-dose therapies,
prompting goodbyes to pharmacy-dispensed drugs like Myalept, a leptin
deficiency med that for years was one of the world’s most expensive with its
$1.26 million yearly cost.



DC Journal: Opinion: Big Pharma Puts Profits Over President Trump’s Agenda
<[link removed]>



The pharmaceutical industry is interested in one thing and one thing only:
charging Americans exorbitant prices for the prescription drugs they sell. This
is why they continue to argue against common-sense solutions, like President
Trump’s “most favored nation” plan to stop Americans from being forced to pay
dramatically higher prescription drug prices than every other developed nation.
They want Americans to stay locked into this bad deal. We are fortunate
President Trump continues to put America first and has been consistently
willing to take on big drug companies so the American people can achieve relief
from their price-gouging and monopolistic, anti-competitive practices.



###



























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>